Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 4/20 | 0.67 |
| ▸ | FKBP1B | P68106 | 2/20 | 0.66 |
| ▸ | PPIA | P62937 | 16/20 | 0.61 |
| ▸ | PPIB | P23284 | 14/20 | 0.61 |
| ▸ | SLCO1B1 | Q9Y6L6 | 3/20 | 0.60 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.59 |
| ▸ | SLCO1B3 | Q9NPD5 | 2/20 | 0.59 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.59 |
| ▸ | PPIF | P30405 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9929661 | 1.00 | ABCB1 (0.67) | ABCB1FKBP1BPPIAPPIBSLCO1B1 | |
| SCHEMBL9979634 | 0.93 | ABCB1 (0.68) | ABCB1FKBP1BPPIAPPIBSLCO1B1 | |
| SCHEMBL9929482 | 0.93 | ABCB1 (0.68) | ABCB1FKBP1BPPIAPPIBSLCO1B1 | |
| SCHEMBL29640429 | 0.93 | ABCB1 (0.68) | ABCB1FKBP1BPPIAPPIBSLCO1B1 | |
| SCHEMBL9929485 | 0.93 | ABCB1 (0.68) | ABCB1FKBP1BPPIAPPIBSLCO1B1 | |
| SCHEMBL16267643 | 0.91 | ABCB1 (0.68) | ABCB1FKBP1BPPIAPPIBSLCO1B1 | |
| SCHEMBL9979652 | 0.91 | ABCB1 (0.68) | ABCB1FKBP1BPPIAPPIBSLCO1B1 | |
| SCHEMBL9978240 | 0.88 | ABCB1 (0.68) | ABCB1FKBP1BPPIAPPIBSLCO1B1 | |
| SCHEMBL9929643 | 0.88 | ABCB1 (0.65) | ABCB1FKBP1BPPIAPPIBSLCO1B1 | |
| SCHEMBL9929645 | 0.88 | ABCB1 (0.65) | ABCB1FKBP1BPPIAPPIBSLCO1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140357569-A1 | CYCLOSPORIN CONJUGATES | UCL BUSINESS PLC (GB) | 2014-12-04 | — | — | US | disclosed |
| US-20120157385-A1 | CYCLOSPORIN CONJUGATES | UCL BUSINESS PLC (GB) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157385-A1 | CYCLOSPORIN CONJUGATES | CYP11B1, SHMT2, MRM1 | ABCB1 70/4885FKBP1B 138/4885PPIA 812/4885 |
| US-20140357569-A1 | CYCLOSPORIN CONJUGATES | CYP11B1, SHMT2, MRM1 | ABCB1 68/4885FKBP1B 141/4885PPIA 855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.